Physician profile

Robert C Nutt

Pediatrics · Wilmington, NC

NPI 1467694661

$1,114.31

in general payments reported to CMS, 2019-2025

10 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$213.06

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Supernus Pharmaceuticals, INC. $363.71 2021-2023 Qelbree
Ironshore Pharmaceuticals INC. $204.38 2022-2023 Jornay Pm
Neurelis, INC. $170.73 2020-2022
Advanced Respiratory, INC $112.27 2020-2021
Baxter Healthcare $85.01 2022
Adlon Therapeutics L.P. $75.94 2021
Corium, LLC $47.42 2023 Azstarys
Biogen, INC. $24.45 2021
Csl Behring $15.69 2023 Hizentra
Eisai INC. $14.71 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Robert C Nutt

$1,114.31

in general payments reported 2019-2025

Years
2020-2023
Top company
Supernus Pharmaceuticals, INC.

https://glasscript.com/doctor/518918/robert-c-nutt

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.